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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2014, KaohsiuAbstract The purpose of this study was to compare the serum interleukin (IL)-23 levels be-
tween rheumatoid arthritis (RA) patients and healthy controls and to determine the correlation
of IL-23 levels with disease activity, joint damage and functional disability in RA. Serum sam-
ples were obtained from 45 patients with RA and 45 healthy controls. The enzyme-linked
immunosorbent assay method was used for quantitative analysis of IL-23. All the RA patients
were assessed for disease activity based on the 28-joint disease activity score, joint damage
based on modified Sharp score, and functional ability using the Health Assessment Question-
naireeDisability Index. The mean serum IL-23 level was much higher among the RA patients
(24.50  13.98 pg/mL) compared to the controls (5.98  3.40 pg/mL; p < 0.01). There was
a significant positive relationship between IL-23 levels and disease activity and questionnaire
scores (p Z 0.003 and 0.020, respectively). On logistic regression analysis, IL-23 levels were
significantly higher in patients with moderate to high disease activity (p Z 0.008, odds
ratioZ 1.073, 95% confidence intervalZ 1.019e1.130) and patients with significant functional
disability (p Z 0.008, odds ratio Z 1.085, 95% confidence interval Z 1.021e1.153). RAave no conflicts of interest to declare.
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338 A.S. Dalila et al.patients have significantly higher levels of serum IL-23. The IL-23 levels correlate well with dis-
ease activity and functional disability but not with radiographic joint damage.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The pathogenesis of rheumatoid arthritis (RA) is believed to
be due to antigen driven helper T-lymphocytes that trigger
a cascade of cytokine production i.e. interleukin (IL)-6, IL-
1, IL-12, IL-17, and tumor necrosis factor (TNFa). These
cytokines and other proinflammatory cells attract macro-
phages into the synovium promoting osteoclastic activity
and proliferation of the synovium leading to destruction of
the cartilage and bones [1]. Beyond academic reasons,
there is a need to explore the role of various cytokines in RA
to formulate targeted therapies to halt the disease
progression.
IL-23 is secreted by activated dendritic cells and mac-
rophages. It is a heterodimeric cytokine composed of p19
and p40 subunits [2,3]. The p40 subunit is shared with IL-12.
Toll-like receptor agonists and interactions with T cells
(CD40/CD40L) were shown to trigger the production of IL-23
[4]. IL-23 can induce chronic inflammation through two
independent pathways. The first pathway is via enhancing
the secretion of IL-17 by non-T cells, and the second
pathway is by the activation of Th17 cells. Once activated,
Th17 cells produce IL-17, IL-6, IL-22, and TNFa and other
factors that are associated with immune-mediated inflam-
mation [5]. The IL-23eIL-17 axis is believed to be the key
orchestrator of numerous proinflammatory pathways.
There is mounting evidence that IL-23 is the culprit cyto-
kine in the pathogenesis of conditions, such as psoriasis [6]
and inflammatory bowel disease [7].
The role of IL-23 in the disease process of RA has spurred
research interest in recent years [8]. The first study to
report the role of IL-23 in RA was published in 2007. Liu
et al. [9] concluded that IL-23, produced by mononuclear
cells in the synovial fluid of RA patients, promotes inflam-
matory responses by inducing IL-8 and IL-6 production from
human fibroblast-like synoviocytes. Two years later (in
2009), Stamp et al. [10] found IL-23 gene expression in
cultured synovial cells isolated from RA patients especially
among those with IL-17A positive cells.
The correlation between IL-23 and disease activity and
damage in RA remains poorly defined. To date, there is a
paucity of clinical studies in this regard to derive firm
conclusions. Hence, this study is an attempt to fill the
knowledge gaps on the clinical significance of IL-23 in RA.Materials and methods
Study design
This was a monocentric, cross sectional, caseecontrol
study that was conducted from January 2013 to August 2013
at the Universiti Kebangsaan Malaysia Medical Centre
(UKMMC), Kuala Lumper, Malaysia. The study proposal wasreviewed, approved and funded by the UKMMC Ethics and
Research Committee (Study Code FF-163-2013).
Sample size calculation
Sample size was calculated by using the Power Sample Size
(PS2; NCSS, Kaysville, UT, USA) software and was performed
based on values from a similar study by Kim et al [11]. The
calculated number of patients needed in each arm was 43.
To provide a slight margin of error given the possibility of
10% drop out, a total of 45 participants were recruited for




of UKMMC. Patients who fulfilled the inclusion and exclusion
criteria were invited to participate in this study. The patients
who provided informed consent were enrolled in this study.
Individuals with poor command of English or Bahasa Malaysia
were briefed with the assistance of an interpreter.
The inclusion criteria for the RA patients were: (1) pa-
tients who fulfilled The American College of Rheumatology
2010 criteria for RA [12]; (2) patients aged 18 years and
above; and (3) patients who were able to provide written or
verbal consent.
The exclusion criteria were: (1) pregnant patients; (2)
patients who were completely unable to read, write, or
understand Malay or English; (3) coexistence of other
autoimmune diseases such as Crohn’s disease, inflamma-
tory bowel disease, psoriatic arthropathy; (4) patients with
active infection; and (5) patients with malignancy.
Controls
Controls were age- and sex- matched healthy individuals.
The aforementioned exclusion criteria were applied to the
controls. Most of the controls in this study were health care
workers.
Study protocol
The baseline demographic data such as age, sex, race, and
body mass index of all participants were recorded. Data on
medications and laboratory parameters were collected by
reviewing the computerized medical records of the RA pa-
tients. These patients were assessed for their Disease Ac-
tivity Score in 28 joints (DAS 28) and had hand and feet
radiographs taken for scoring. Health Assessment Ques-
tionnaireeDisability Index (HAQ-DI) scores were deter-
mined by interviewing patients. The interview was
conducted by a single interviewer. The RA patients and the
controls were tested for serum IL-23 levels.







Age, y 54.78  7.07 54.00  7.4 0.611
Height, cm 156.5  6.5 157.38  7.4 0.558
Weight, kg 59.9  12.3 60.73  13.3 0.763
BMI, kg/m2 24.0  4.6 24.18  5.5 0.852
Sex
Male 5 (11.1) 5 (11.1) 1.000
Female 40 (88.9) 40 (88.9)
Ethnicity
Malay 24 (53.3) 40 (88.9) 0.057
Chinese 9 (20) 4 (8.9)
Indian 9 (20) 1 (2.2)
Others 3 (6.7) 0 (0)
Education level
Tertiary 10 (22.2) 15 (33.3) 0.137
Secondary 23 (51.1) 25 (55.6)
Primary 12 (26.7) 5 (11.1)
Data are presented as n (%) or mean  SD.
BMI Z body mass index.
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DAS 28
DAS 28 is a quantitative measure of disease activity in RA. It
has a validated formula that is used worldwide especially in
clinical trials [13]. The four parameters used to calculate
DAS 28 are; number of swollen joints, number of tender
joints, C-reactive protein or erythrocyte sedimentation
rate (ESR), and the patient’s global assessment [14].
A DAS 28 score of 3.2 and above indicate moderate to
severe disease activity whereas a value of below 3.2 refers
to remission to low disease activity [15].
Modified sharp score
Sharp score refers to a radiographic scoring of erosions and
joint space narrowing of hands and feet in RA, which was
first described in 1971 [16]. The modified version was pro-
posed in 1985 by Sharp et al. [17] and was further improved
by van der Heijde in 1996 [18]. To date, this is the radio-
graphic scoring method of choice in clinical trials.
The scoring was performed by a single radiologist who
was blinded to the participants. The modified Sharp score
(MSS) includes, in each hand, 16 areas for erosions, and 15
areas for joint space narrowing, and, in each foot, 6 areas
for erosions and 6 areas for joint space narrowing. The
erosion score per joint of the hands can range from 0 to 5.
Overall, the maximum MSS sums up to 448.
HAQ-DI
The HAQ-DI is the most widely used tool for functional
assessment in RA [19]. The HAQ-DI assesses a patient’s level
of functional ability involving fine movements of the upper
extremity and locomotor activities of the lower extremity.
There are 20 questions in eight categories that represent a
comprehensive set of common daily activitiesddressing,
rising, eating, walking, and hygiene. Higher scores indicate
more disability (0 Z without any difficulty; 1 Z with some
difficulty; 2Z with much difficulty; and 3Z unable to do).
A HAQ-DI score of 1 and above indicates significant (mod-
erate to very severe) functional disability [20].
Serum IL-23 level
The serum concentration of IL-23 was measured quantita-
tively using a commercial enzyme-linked immunosorbent
assay kit (eBioscience, San Diego, CA, USA). The medical
laboratory technologists who processed the samples were
blinded to the participants.
Statistical analysis
All data were analyzed using SPSS version 21.0 (SPSS Inc.,
Chicago, IL, USA). The continuous variables were tested for
normality using Kolmogorov Smirnov test. Data with normal
distribution were analyzed using independent t-test and
expressed as mean  standard deviation. The data that
were skewed or with no particular distribution, by contrast,
were analyzed using ManneWhitney U test and expressed as
median  range. The relationship between two continuous
variables was determined using regression analysis. Vari-
ables that were significant on univariate analysis were
further analyzed using multivariate analysis to adjust for
confounders. A p value of <0.05 was considered significant.Results
Baseline demographic data
A total of 45 RA patients and 45 healthy controls were
enrolled in this study. Women outnumbered men; 80
(88.9%) versus 10 (11.1%). The participants were predomi-
nantly Malays for both the RA patients (53.3%) and the
controls (88.9%). The mean age of RA patients was
54.3  11.5 years and controls were aged 54.0  7.4 years.
The sociodemographic characteristics were matched be-
tween the RA patients and controls (Table 1).
Clinical characteristics of RA patients
Table 2 summarizes the clinical characteristics of RA pa-
tients. A higher proportion of the patients (60%) were either
in remission or with low disease activity compared to
moderate to severe disease activity (40%). Erosive disease
was present in 30 patients (66.7%) whereas joint space
narrowing was detected in 32 patients (71.1%). The ma-
jority of patients (25 patients, 64.1%) were on disease-
modifying anti-rheumatic drugs (DMARD) monotherapy.
The conventional DMARDs of the cases include metho-
trexate, sulfasalazine, leflunomide, and hydroxy-
chloroquine. The most frequently used DMARD was
methotrexate (60%). Six patients (13.3%) were on biologic
DMARDs.
Comparison of serum IL-23 levels between the
patients with RA and controls
The mean serum IL-23 levels was much higher among the RA
patients (24.50  13.98 pg/mL) compared to the controls
(5.98  3.40 pg/mL). This difference was statistically sig-
nificant (p < 0.01).








CRP, mg/dL 0.69  0.74
ESR, IU/mL 58.78  28.68
HAQ-DI
HAQ < 1 35 (77.8)
HAQ  1 10 (22.2)
MSS
Erosion score 13.56  18.40
JSN score 21.56  26.3
Total score 33.58  43.2
Swollen joint count 1.07  1.9
Tender joint count 2.29  4.0
VAS 50.22  16.2
DAS 28 3.15  1.17
Remission: low disease activity 27 (60)
Moderate: high disease activity 18 (40)
Data are presented as n (%) or mean  SD.
CRP Z C reactive protein; DAS 28 Z 28 joint based disease
activity score; ESR Z erythrocyte sedimentation rate; HAQ-
DI Z Health Assessment QuestionnaireeDisability Index;
JSN Z joint space narrowing; MSS Z modified Sharp score;
VAS Z visual analog score.
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The RA patients with moderate to high disease activity (DAS
28  3.2) had significantly higher mean IL-23 levels
compared to those in remission to mild disease activity (DAS
28 < 3.2; pZ 0.003). Likewise, the patients with significant
functional disability (HAQ-DI  1) had higher mean IL-23
levels (p Z 0.020; Fig. 1). On linear regression analysis,
DAS 28 and HAQ-DI had a significant positive relationship
with the IL-23 levels (Fig. 2). The strength of the relation-
ship was strong for both DAS 28 and HAQ-DI as the r valueFigure 1. Mean IL 23 levels acrwas within the range 0.4e0.75. There was no significant
association between radiographic joint damage and IL-23
levels.
Logistic regression analysis
Variables that were significant on univariate analysis (dis-
ease activity and functional disability), were further
analyzed. Adjusted odds ratio with the 95% confidence in-
terval were determined using the logistic regression model.
IL-23 levels were significantly higher in RA patients with
moderate to high disease activity (p Z 0.008, odds
ratioZ 1.073, 95% confidence intervalZ 1.019e1.130) and
with significant functional disability (p Z 0.008, odds
ratio Z 1.085, 95% confidence interval Z 1.021e1.153).
Discussion
Preliminary research findings on IL-23 in RA, although
experimental, do suggest that this cytokine may be one of
the molecular culprits in RA. Both animal and human
studies have demonstrated that IL-23 regulates the forma-
tion of IL-17 and CD4þ T cells in the presence of joint
inflammation [21]. Recently, a meta-analysis on IL-23 re-
ceptor polymorphism highlighted that this gene may be
associated with an increased risk of developing RA [22].
This study confirmed that circulating IL-23 levels were
significantly higher in RA patients compared to healthy
controls (p < 0.01). Similar findings were observed by Guo
et al. [5] in a study conducted in China. Likewise, Hillyer
et al. [3] detected IL-23 in the synovial tissues of RA pa-
tients. Apart from RA, reports have implicated the role of
this cytokine in many other autoimmune diseases such as
psoriasis, Crohn’s disease, ulcerative colitis, and in malig-
nancies [6,7].
Although many studies have demonstrated an elevated
expression of IL-23 in the sera as well as in the synovial
fibroblasts of patients with RA, Brentano et al. [23] had
conflicting findings. Soluble IL-23 was not detectable or
found at very low levels in their RA patients. Melis et al. [8]
found that RA patients had higher serum levels of IL-23
(mean 50.92 pg/mL) compared to healthy controls (meanoss the various subcategories.
Figure 2. The relationship of IL 23 levels with DAS 28 and
HAQ-DI scores.
Interleukin 23 in rheumatoid arthritis 34115.10 pg/mL) and psoriatic patients (mean 11.87 pg/mL).
The differences across the groups in the above-mentioned
study, however, did not reach statistical significance
(p Z 0.320).
One of the main findings of this study is the significant
positive relationship between the IL-23 levels and DAS 28
(r Z 0.443, p Z 0.003). Thus, higher IL-23 levels reflect
higher disease activity in RA. Melis et al. [8] reported that
the degree of intimal lining layer hyperplasia in RA patients
was strongly associated with IL-23 levels in the joints.
Rasmussen et al. [2], who had findings consistent with our
study results, demonstrated that IL-23 levels were signifi-
cantly associated with DAS 28 score and ESR. The produc-
tion of IL-23 is promoted by several factors including the
innate immune receptors such as Toll-like receptor, dectin-
142, and the CD40 ligand [7]. In keeping with the proin-
flammatory properties of this cytokine, serum IL-23 levels
in RA patients showed a decreasing trend after TNF
blockade [24].
We found no association between radiographic joint
damage and IL-23 levels; contradicting the findings by Guo
et al. [5] who demonstrated a positive correlation between
IL-23 levels and knee joint erosions. The possible explana-
tion for the discordance in the findings could be that in theabove study, only knee X-rays were analyzed. We, however,
used radiographs of the hands and feet for scoring. A strict
comparison, therefore, cannot be made. Rasmussen et al.
[2] had findings analogous to ours. In their study, plasma
levels IL-23 after 12 months of treatment correlated with
DAS28 and ESR, but not with the MSS. Consistent with these
findings, the mean IL-23 levels did not differ significantly
between patients with erosive disease and non-erosive
disease. This finding indicates that IL-23 levels correlate
with disease activity but not with disease damage.
So far, no studies have looked into the association be-
tween IL-23 levels and HAQ-DI. We have demonstrated a
significant association between IL-23 levels and HAQ-DI
(pZ 0.008). Based on our analysis, beyond disease activity,
IL-23 appears to predict patient-reported functional
disability. Similarly, in RA, several other cytokines have
been proven to have relationships with functional mea-
sures. Beckham et al. [25] reported that plasma TNFa and
soluble IL-2 receptors had significant correlations with
functional outcomes such as grip strength and Arthritis
Impact Measurement Scale scores.
This study has several drawbacks. A greater proportion
of the RA patients in this study had seronegative disease
(60%). In most RA cohorts, seropositive disease is more
prevalent and can be as high as 97.8% [26,27]. The sample
size which is relatively small in this study may be partially
explanatory for the striking difference with previous RA
studies in terms of frequency of seropositivity. Besides, as
with other cytokines and biomarkers, IL-23 levels tend to
fluctuate in the blood circulation. Ideally, each participant
should have been tested for IL-23 levels on 2e3 separate
occasions and the average measurement could have been
used in the analysis. The completion of the HAQ-DI ques-
tionnaire was interviewer-assisted. Self-completed ques-
tionnaires are less prone to investigator bias. Moreover,
joint damage was assessed based on MSS. Ultrasound is a
more sensitive tool to assess for joint erosions in RA [28].
Early or mild erosions may be missed by plain radiographs.
In conclusion, IL-23 levels were markedly elevated in
patients with RA compared to healthy controls. The IL-23
levels correlated significantly with disease activity and
functional disability but not with radiographic joint dam-
age. The findings of this study have clinical implications.
Our data suggest that anti-IL-23 is a potential therapeutic
option in the treatment of RA. The ongoing clinical trials
evaluating the role of ustekinumab (anti-IL-12 and IL-23) in
RA will hopefully validate our findings.References
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